S. Baka

Combination chemotherapy with paclitaxel and gemcitabine followed by concurrent chemoradiotherapy in non-operable localized non-small cell lung cancer. A hellenic cooperative oncology group (HeCOG) phase II study.

N. Pavlidis, H. Gogas, G. Fountzilas, 2007, Anticancer research.

Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancer

M. Kriegsmann, A. Stenzinger, K. Samitas, 2021, ESMO open.

Phase III study comparing sequential versus alternate administration of cisplatin-etoposide and topotecan as first-line treatment in small cell lung cancer.

S. Agelaki, D. Mavroudis, V. Georgoulias, 2010, Anticancer research.

Suggestions, Opinions and Recommendations for the Diagnosis, Management, Treatment and Surveillance of Lung Cancer

J. Dahabreh, S. Murray, C. Kosmas, 2011 .

1194MO Canakinumab (CAN) + docetaxel (DTX) for the second- or third-line (2/3L) treatment of advanced non-small cell lung cancer (NSCLC): CANOPY-2 phase III results

B. Halmos, L. Paz-Ares, B. Cho, 2021, Annals of Oncology.

ABREAST: a prospective, real-world study on the effect of nab-paclitaxel treatment on clinical outcomes and quality of life of patients with metastatic breast cancer

C. Papadimitriou, G. Aravantinos, A. Psyrri, 2020, Breast Cancer Research and Treatment.